Amplify and train CAR-T cells to deliver more potent anti-cancer activity—ultimately, enabling the cure of previously fatal lymphomas and leukemias.
Dr. Harris Goldstein
people are diagnosed with Non-Hodgkin’s lymphoma in the U.S annually.
patients die from Non-Hodgkin’s lymphoma every year in the US.
Lymphoma impacts the lymph system, which functions within the immune system—meaning the place that fights infection and disease in your body is under attack by this type of cancer. While the infected cells begin in places such as lymph nodes, the spleen, and digestive tract, it is a rapidly progressive disease that can aggressively grow and spread.
We want to train cells to deliver more potent anti-cancer activity. We will work with highly immunodeficient mice to create a model to evaluate our CAR-T cell therapy approach. It is our near-term aim to advance into clinical trial design and implementation to treat relapsed lymphoma and leukemia. To get there, our year-long Phase 1 will focus on perfecting concept, experimental protocol, and initial testing.
|Project Length||1 year|
|Goal||Launch preliminary research to create the most effective strategy for CAR-T cells to attack malignant cells|